April 14, 2020: A treatment developed by AstraZeneca Plc and Merck & Co Inc for a rare genetic disorder was approved by the U.S. Food and Drug Administration Tuesday, the companies said.
Koselugo has been approved for the treatment of paediatric patients aged two years and older with a type of neurofibromatosis, which is a crippling genetic disease affecting one in every 3,000 to 4,000 individuals. https://fda.einnews.com/article/514537392?lcf=8DWPqPuUsDVNDakfEIxsCA%3D%3D
